Dec 10 (Reuters) - Siga Technologies' ( SIGA ) antiviral
drug tecovirimat did not reduce the time to lesion resolution or
have an effect on pain among adults affected by the clade II
strain of mpox, according to a National Institutes of Health
study published on Tuesday.